University of Indonesia

education📍 Depok, Indonesia
University of Indonesia
2
Alpha-gal Syndrome Publications
8
Alpha-gal Syndrome Researchers

Associated Institutions

Oxford University Clinical Research Unit Indonesia
related

Publications

sialidase interaction with Neu5Ac α-Gal sialic acid receptors by observation and its impact on monolayers cellular behavior structure.

Kurnia RS, Soebandrio A, Harun VH, Nugroho CMH, Krisnamurti DGB, et al.
Journal of advanced veterinary and animal research •

This study aims to evaluate the effect of sialidase treatment on monolayer cell behavior using computational screening and an approach to demonstrate interaction between enzyme-based drugs and ligands in host cells. The study was carried out by molecular docking analysis used to predict the interactions between atoms that occur, followed by genetic characterization of sialidase from a wild isolate. Sialidase, which has undergone further production and purification processes exposed to chicken embryonic fibroblast cell culture, and observations-based structural morphology of cells compared between treated cells and normal cells without treatment. Based on an study, sialidase has an excellent binding affinity with Neu5Acα (2.3) Gal ligand receptor with Gibbs energy value (∆G)-7.35 kcal/mol and Ki value of 4.11 µM. Wild isolates in this study have 99.1%-100% similarity to the plc gene, NanH, and NanI genes, while NanJ shows 93.18% similarity compared to the reference isolate from GenBank. Sialidase at 750 and 150 mU may impact the viability, cell count, and cell behavior structure of fibroblast cells by significantly increasing the empty area and perimeter of chicken embryo fibroblast (CEF) cells, while at 30 mU sialidase shows no significant difference compared with mock control. Sialidase-derived has the capacity to compete with viral molecules for attachment to host sialic acid based on analysis. However, sialidase treatment has an impact on monolayer cell fibroblasts given exposure to high doses.

Pharmacogenetic application in personalized cancer treatment.

Kristyanto H, Utomo AR
Acta medica Indonesiana •

Pharmacogenetic is broadly understood as study or clinical testing of genetic variations that contribute to differing response to drugs. In cancer treatment, applications of pharmacogenetic cover three areas: avoidance of adverse drug reaction (ADR), selection of treatment options, and prediction of cancer recurrence. Patients with genetic variations in UGT1A1 and DPYD genes are hypersensitive to Irinotecan and 5-Fluorouracil (5FU) respectively. Therefore, the chance for the patients to suffer from ADR from using those drugs can be predicted a priori by simple genetic tests. Secondly, the efficacy of targeted therapy drugs such as Cetuximab and Erlotinib, or non- targeted agents such as temozolomide and nitrosourea has been influenced by the presence of certain genetic or epigenetic markers in tumors. Lastly, microarray analysis to evaluate 70-gene expression profile in breast cancer samples has been shown in recent studies to predict probability of breast cancer recurrence. Patients whose tumors have been determined to have low probability score based on the gene expression profile may omit chemotherapy altogether, avoiding unnecessary therapeutic side effects. In summary, pharmacogenetic tests help patients, their caregivers, and doctors in deciding the best treatment options with favorable chance of success, as well as saving overall treatment costs.